India’s own Covid-19 vaccine effective as inoculation drive gathers steam Issued on: 05/03/2021 - 12:48 A medic administers COVAXIN, an Indian government-backed experimental COVID-19 vaccine, to a health worker during its trials, at the Gujarat Medical Education & Research Society in Ahmedabad, India, 26 November 2020. REUTERS - AMIT DAVE Text by: Pratap Chakravarty 4 min India’s first locally-developed Covid-19 vaccine posted 81 percent interim efficacy in late stage trials involving nearly 26,000 people, putting to rest doubts and debate over the shots and brightening prospects of its export to Brazil, and other countries. Advertising Read more Bharat Biotech, the manufacturer, hailed the verdict as an important milestone in vaccine discovery, for science and our fight against coronavirus and said the exercise involved the largest cluster of volunteers in a clinical trial in India.
LT Foods picks 30% stake in Dutch packaged foods firm Leev LT Foods, which sells packaged rice under the Daawat, Heritage and Royal brands, on 20 January 2021 announced the acquisition of 30% stake in Leev.nu, a Netherlands-based organic specialty food company. The move comes just weeks after the company expanded its manufacturing capabilities in Europe by commissioning a new packaging line at its plant in Rotterdam, Netherlands. LT Foods has five processing facilities in India, two packaging units and one ready-to-heat facility in the US, and one processing facility in Rotterdam. The acquisition deal through its subsidiary Nature Bio Foods BV has an option to acquire further 21% stake after five years. A private equity investor Did-It, with experience in worldwide trading of organic products, has also taken a stake in Leev.nu.
January 20, 2021 × LT Foods says the acquisition has been done in line with the long term growth plans LT Foods Ltd on Wednesday said that its subsidiary Nature Bio Foods BV, has acquired 30 per cent stake in a Netherland-based Leev.nu for an undisclosed amount. The company said the acquisition has been done with an option of acquiring a further stake of 21 per cent at the end of five years. Leev.nu, which is an organic specialty food company, is known for a product portfolio consisting of breakfast bars, healthy snacks, baking range & gluten free and low sugar products . It is also expanding its product portfolio into organic whole grains categories such as oats and flax seeds.
LT Foods picks 30% stake in Netherlands-based Leev through subsidiary LT Foods Ltd sells packaged rice under the Daawat, Heritage and Royal brands. This acquisition gives LT Foods subsidiary NBF BV a reach to the consumers directly via the mainstream distribution strength of Leev. (Mint)Premium Share Via Read Full Story New Delhi: LT Foods Ltd, which sells packaged rice under the Daawat, Heritage and Royal brands, on Wednesday said it has acquired a 30% stake in Leev.nu, a Netherlands-based packaged foods company, through its subsidiary Nature Bio Foods BV. The transaction allows Nature Bio Foods (NBF BV) an option to acquire a further 21% stake in Leev.nu at the end of five years, the company said in a statement.
LT Foods acquires 30 pc stake in Netherlands-based Neev.nu ANI | Updated: Jan 20, 2021 14:23 IST New Delhi [India], January 20 (ANI): LT Foods Ltd on Wednesday announced the acquisition of 30 per cent stake in Leev.nu BV, a Netherlands-based organic specialty food company. The acquisition deal through its subsidiary Nature Bio Foods BV has an option to acquire further 21 per cent stake after five years. A private equity investor called & Did-It with experience in worldwide trading of organic products has also taken a stake in Leev.nu BV. Vijay Kumar Arora, Chairman and Managing Director of LT Foods, said Leev.nu will now have access to 100 per cent organic products grown by Nature Bio Foods s network of 60,000-plus organic farmers which cultivate in 80,000 hectares of certified organic land in India.
3314 A health worker takes part in the dry run of the Covid vaccine at the Primary Health Centre in Sector 16, Panchkula. file Open house: What are your apprehensions about covid vaccination programme? Public scrutiny is a must The approval for the emergency use of the Covaxin to Serum Institute s Covishield and Bharat Biotech by the Drugs Controller General of India (DCGI) had cleared the last hurdle before the start of the vaccination drive in India. The government appointed Subject Expert Committee was convinced that Covaxin s inactivated virus may be more effective against mutations. Lack of transparency surrounding trials data, fast-tracking of data scrutiny and doubts over vaccine dosage and mutations have raised concerns. But India is no exception here. Each country is adopting different approaches. Globally, many view approving of vaccines to combat the Covid pandemic as inordinate haste. The DCGI must make a clean analysis of the submitted data and continue to share reviews of the Phase 3 trials. Vaccine will test government s skill for answering inconvenient questions. It mustn t avoid public scrutiny.